文献速递核素与放射性配体治疗

靶向C-X-C趋化因子受体4的清髓性放射性配体治疗用于晚期多发性骨髓瘤

Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma.
PubMed 文献 · Clin Nucl Med · 2025-03-05

38例复发/难治性多发性骨髓瘤患者接受40个周期的CXCR4靶向[90Y]Y-PentixaTher或[177Lu]Lu-PentixaTher治疗,至预处理化疗开始日白细胞下降81.8%、中性粒细胞下降69.4%(均P<0.0001),58起不良事件中仅1起(1.7%)≥3级;39/40周期成功进行预处理化疗,39/39周期完成造血干细胞移植,37/39周期(94.9%)成功中性粒细胞植入。

要点

  • CXCR4靶向放射性配体治疗至预处理化疗日白细胞下降81.8%、中性粒细胞下降69.4%(均P<0.0001)。
  • 40个周期中58起不良事件,仅1起(1.7%)≥3级。
  • 39/40周期(97.5%)成功预处理化疗,37/39周期(94.9%)成功中性粒细胞植入。

核心结论

  • CXCR4靶向放射性配体治疗在复发/难治性多发性骨髓瘤中产生相关清髓效应;在追加预处理化疗后行造血干细胞移植,绝大多数病例达到成功中性粒细胞植入。

研究设计与样本

  • 38例复发/难治性多发性骨髓瘤患者接受40个周期CXCR4靶向[90Y]Y-PentixaTher或[177Lu]Lu-PentixaTher治疗,在放射性配体治疗前(第1天)、第2天及预处理化疗开始日(中位第10天)监测血液学参数。

主要发现

  • 至预处理化疗开始日,白细胞下降81.8%、中性粒细胞下降69.4%(均P<0.0001),血小板下降63.1%(P<0.0001),血红蛋白下降9%(P=0.002)。
  • 共观察到58起不良事件,其中≥3级1起(1/58,1.7%)。
  • 39/40周期(97.5%)成功进行预处理化疗;预处理化疗后39/39周期(100%)实施造血干细胞移植,其中37/39周期(94.9%)达到成功中性粒细胞植入。

关键数值与推荐

  • 器官毒性实验室参数按常见不良事件评价标准(CTCAE)5.0版分级,并应用Cairo-Bishop分类识别放射性配体治疗所致实验室肿瘤溶解综合征。
  • 清髓动力学通过治疗前第1天、第2天及预处理化疗开始日(中位第10天)的血液学参数监测评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Markedly expressed on hematopoietic stem cells, C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) has been used in relapsed/refractory (r/r) MM to prepare for hematopoietic stem cell transplantation (HSCT). We aimed to determine the myeloablative efficacy of CXCR4 RLT in MM patients and assessed the safety profile of this treatment. METHODS: Thirty-eight patients with r/r MM were treated with 40 cycles of CXCR4-targeting [ 90 Y]Y-PentixaTher or [ 177 Lu]Lu-PentixaTher. Myeloablative dynamics were closely monitored by examining hematologic parameters before the application of RLT (day 1), on day 2, and on the start day of conditioning chemotherapy (CON, median day 10). Laboratory parameters evaluating organ toxicity were collected and categorized following the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Cairo-Bishop classification was also applied to identify patients experiencing laboratory tumor lysis syndrome (TLS) caused by RLT. After CON, we determined the rate of patients receiving hematopoietic stem cell transplantation (HSCT) followed by successful neutrophile engraftment. RESULTS: Forty cycles of CXCR4-directed RLT were applied. Myeloablative effects resulted in an 81.8% decline in leukocytes and a 69.4% decrease in neutrophil levels till the day of CON ( P <0.0001, respectively), followed by platelets (63.1%; P <0.0001) and hemoglobin (9%; P =0.002). We observed 58 AE Events (1/58 [1.7%], ≥ grade 3). CON could be applied successfully after 39/40 (97.5%) cycles. After CON, in 39/39 (100%) of the cycles, HSCT was conducted, and successful neutrophil engraftment was reached after 37/39 (94.9%) of these cycles. CONCLUSIONS: CXCR4-directed RLT exerted relevant myeloablative effects. When performing HSCT after applying additional CON, successful neutrophile engraftment was reached in the vast majority of the cases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dreher N, Dörrler AL, Kraus S, et al. Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma. Clin Nucl Med. 2025. PMID: 40323995. doi:10.1097/RLU.0000000000005813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。